<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157919">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01695993</url>
  </required_header>
  <id_info>
    <org_study_id>UCCS1202</org_study_id>
    <secondary_id>R01AT007474-01A1</secondary_id>
    <nct_id>NCT01695993</nct_id>
  </id_info>
  <brief_title>Alternative Approaches for Nausea Control</brief_title>
  <official_title>Alternative Approaches for Nausea Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Alternative Medicine (NCCAM)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      216 Chemotherapy-naïve, female breast cancer patients about to begin chemotherapy and who
      expect to have nausea, will be entered.  Participants will be randomized to one of three
      study arms: Arm 1: Version 1 handout; Arm 2: Version 1 handout + Version 1 relaxation MP3 +
      acupressure bands; Arm 3: Version 2 handout + Version 2 relaxation MP3 + acupressure bands.

      Hypothesis:   Acupressure bands provided with the relaxation MP3 will be effective in
      controlling chemotherapy-induced nausea
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Earlier research has shown that the effectiveness of acupressure bands in reducing nausea
      could be enhanced by boosting patients' expectations of the bands' efficacy. The present
      study seeks to confirm and extend these findings in a multi-site, 3-arm, randomized,
      controlled study of 216 breast cancer patients beginning chemotherapy who expect to have
      nausea.  All patients will receive a standardized antiemetic regimen.  Arm 1: Version 1 of
      Handout; Arm 2: Version 1 of handout + Version 1 relaxation MP3 + acupressure bands; Arm 3:
      Version 2 of handout + Version 2 of relaxation MP3 + acupressure bands.  The investigators
      hypothesize that acupressure bands provided with the relaxation MP3 will be effective in
      controlling chemotherapy-induced nausea. The two versions of the handout and MP3 are being
      examined to determine what is the most effective way to deliver the intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>patient report nausea diary</measure>
    <time_frame>five days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Nausea and emesis will be measured by a patient report diary completed by patients over a five-day period.  Each day is divided into four segments (morning, afternoon, evening, night) in which patients report the severity of nausea and number of vomiting episodes for each period of the day.  Severity of nausea is assessed on a 7-point rating scale, anchored at one end by 1 = &quot;Not at all nauseated&quot; and at the other end by 7 = &quot;Extremely nauseated.&quot;  Vomiting episodes will be recorded for the same time intervals.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Nausea</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive only the Version 1 handout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive the Version 1 handout, the Version 1 MP3, and acupressure bands.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the Version 2 handout, the Version 2 MP3, and acupressure bands.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Acupressure bands</intervention_name>
    <description>Bilateral acupressure wrist bands (Sea-Band International, England), given to patients in trial Arms 2 and 3, are widely available and inexpensive (under $6.00 a pair).</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Version 1 handout</intervention_name>
    <description>The Version 1 handout has less information concerning the acupressure bands than the Version 2 handout.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Version 1 MP3</intervention_name>
    <description>Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Version 2 handout</intervention_name>
    <description>The Version 2 handout has more information concerning the acupressure bands than the Version 1 handout.</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Version 2 MP3</intervention_name>
    <description>Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. The MP3 (for subjects randomized to Arm 3) has some additional information in it regarding relaxation.</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be female.

          -  Have a diagnosis of breast cancer, any stage.

          -  Be chemotherapy naïve and about to begin her first course of chemotherapy.

          -  Be scheduled to receive one of the following four common chemotherapy regimens with
             the specified antiemetic regimen.  They are:

               1. Chemotherapy regimen: Doxorubicin/cyclophosphamide. Antiemetic regimen:
                  Aprepitant + palonosetron + dexamethasone on Day 1 and aprepitant +
                  dexamethasone on Days 2 &amp; 3.

               2. Chemotherapy regimen: Doxorubicin/cyclophosphamide/docetaxel.  Antiemetic
                  regimen: Aprepitant + palonosetron + dexamethasone on Day 1 and aprepitant +
                  dexamethasone on Days 2 &amp; 3.

               3. Chemotherapy regimen: Docetaxel/carboplatin. Antiemetic regimen: Palonosetron on
                  Day 1 + dexamethasone on Days 1, 2, &amp; 3.

               4. Chemotherapy regimen: Docetaxel/cyclophosphamide. Antiemetic regimen:
                  Palonosetron on Day 1 + dexamethasone on Days 1, 2, &amp; 3.

        Note: Fosaprepitant will be allowed in place of aprepitant, and either granisetron or
        ondansetron, on one or more days, will be allowed in place of palonosetron.

          -  Have a response of  &gt; 3 or greater on a question assessing expected nausea as
             assessed on a 5-point Likert-scale anchored at one end by 1 = &quot;I am certain I WILL
             NOT have this,&quot; and at the other end by 5 = &quot;I am certain I WILL have this.&quot;

          -  Be able to read English (since the assessment materials are in printed format).

          -  Be 18 years of age or older and give written informed consent.

        Exclusion Criteria:

          -  Have clinical evidence of lymphedema, current bowel obstruction, or symptomatic brain
             metastases, as determined by their treating oncologist.

          -  Be receiving concurrent radiotherapy or interferon.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Roscoe, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenine Hoefler, M.S.</last_name>
    <phone>585.276.3559</phone>
    <email>Jenine_Hoefler@URMC.Rochester.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Lynne Tarquini, RN, BSN, CCRP Tarquini, RN, BSN, C</last_name>
      <phone>716-845-3008</phone>
      <email>cab21@healthresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Roswell Park</last_name>
      <phone>877-275-7724</phone>
      <email>ASKRPCI@RoswellPark.org</email>
    </contact_backup>
    <investigator>
      <last_name>Tracey O'Connor, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Associates of Central New York</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coleen A Dillenbeck, MA, CCRC</last_name>
      <phone>315-472-7504</phone>
      <phone_ext>1360</phone_ext>
      <email>cdillenbeck@hoacny.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey J. Kirshner, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenine Hoefler, M.S.</last_name>
      <phone>585-276-3559</phone>
      <email>Jenine_Hoefler@URMC.Rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph A Roscoe, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rochester General Hospital's Lipson Cancer and Blood Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Andrews, MBA, CCRC</last_name>
      <phone>585-922-4040</phone>
      <email>Caroline.Andrews@rochestergeneral.org</email>
    </contact>
    <investigator>
      <last_name>Peter Bushunow, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 6, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>Joseph Roscoe</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Nausea</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Expectancy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nausea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
